161 related articles for article (PubMed ID: 9049581)
1. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
Spina E; Gitto C; Avenoso A; Campo GM; Caputi AP; Perucca E
Eur J Clin Pharmacol; 1997; 51(5):395-8. PubMed ID: 9049581
[TBL] [Abstract][Full Text] [Related]
2. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant activity of 2-hydroxydesipramine.
Nelson JC; Mazure C; Jatlow PI
Clin Pharmacol Ther; 1988 Sep; 44(3):283-8. PubMed ID: 3416551
[TBL] [Abstract][Full Text] [Related]
4. 2-Hydroxydesipramine and desipramine plasma levels: how are they related to antidepressant response?
Stern SL; Cooper TB; Nelson LD; Johnson MH; Suckow RF
Int Clin Psychopharmacol; 1996 Dec; 11(4):219-27. PubMed ID: 9031987
[TBL] [Abstract][Full Text] [Related]
5. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.
Cooke RG; Warsh JJ; Stancer HC; Reed KL; Persad E
Clin Pharmacol Ther; 1984 Sep; 36(3):343-9. PubMed ID: 6467794
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
[TBL] [Abstract][Full Text] [Related]
7. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
8. Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.
Shen HW; Yu AM
Drug Metab Lett; 2009 Dec; 3(4):234-41. PubMed ID: 19995332
[TBL] [Abstract][Full Text] [Related]
9. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
[TBL] [Abstract][Full Text] [Related]
10. Phenobarbital induces the 2-hydroxylation of desipramine.
Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of desipramine metabolism.
Musa MN; Miescke KJ
Int J Clin Pharmacol Ther; 1994 Mar; 32(3):126-30. PubMed ID: 8205373
[TBL] [Abstract][Full Text] [Related]
13. Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine.
Spina E; Arena A; Pisani F
Ther Drug Monit; 1987 Jun; 9(2):129-33. PubMed ID: 3617150
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of 2-hydroxydesipramine plasma concentrations.
Nelson JC; Bock JL; Jatlow PI
Clin Pharmacol Ther; 1983 Feb; 33(2):183-9. PubMed ID: 6822031
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
17. Concurrent treatment of nonresistant major depression with desipramine and lithium: a double-blind, placebo-controlled study.
Bloch M; Schwartzman Y; Bonne O; Lerer B
J Clin Psychopharmacol; 1997 Feb; 17(1):44-8. PubMed ID: 9004056
[TBL] [Abstract][Full Text] [Related]
18. 2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults.
Stern SL; Ribner HS; Cooper TB; Nelson LD; Johnson MH; Suckow RF
J Clin Psychopharmacol; 1991 Apr; 11(2):93-8. PubMed ID: 2056147
[TBL] [Abstract][Full Text] [Related]
19. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
[TBL] [Abstract][Full Text] [Related]
20. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
